Two Top Stocks To Ponder On: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

earnings estimates

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) closed at $1.57 on the last trading session with an decrease of -8.19%, whereas, it previously closed at $1.71. The company has a market capitalization of $21.27 Million. The company traded shares of 312061 on the trading day while its three month average volume stands at 843.21 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) produced diluted EPS of -2.24. The EPS estimate for next year as estimated by analysts is at -0.31 while EPS for next quarter is estimated at -0.26. Earnings per Share growth for this year is reported at 80.8, while the analysts estimated the EPS growth for next year at -0.31% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -17.1%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) stands at 3.22 and Price to Book or P/B for the most recent quarter stands at 1.3. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) are reported at 3.5 and 3.9 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) stands at -103.8, -366.4 and -74.5 respectively

The trailing twelve month Revenue of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is reported at 6.6 Million with income of -9300000. The outstanding shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) are 13.55 Million. The institutional Ownership of the shares of 4.6 stands at 0.80%, this figure is decreased -6.87 in the last six months. The insider ownership for the shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is ticked at 4.32%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is the Mean Target Price estimated by the analysts which stands at 9.95. The 52 week high of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is placed at 6.90 and 52 week low is standing at 1.03.

Performance wise the shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) fell down -7.65% for the week, it also fell -6.55% for the monthly performance, while for the quarter it went down 0.64%. The shares decrease -35.37% for the half year and flew up for the Year-To-Date performance. The shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) shrinked -67.66% for the yearly performance.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) closed at $69.93 on the last trading session with an increase of 2.57%, whereas, it previously closed at $68.18. The company has a market capitalization of $4.05 Billion. The company traded shares of 1.76 Million on the trading day while its three month average volume stands at 2.23 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) produced diluted EPS of -2.12. The EPS estimate for next year as estimated by analysts is at -0.37 while EPS for next quarter is estimated at -0.26. Earnings per Share growth for this year is reported at 88.4, while the analysts estimated the EPS growth for next year at -0.37% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 37.9%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) stands at 18.19 and Price to Book or P/B for the most recent quarter stands at 33.46. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) are reported at 2.1 and 2.4 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Tandem Diabetes Care, Inc. (NASDAQ:TNDM) stands at -59.4, -114.7 and -38.1 respectively

The trailing twelve month Revenue of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is reported at 222.6 Million with income of -112900000. The outstanding shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) are 57.89 Million. The institutional Ownership of the shares of 87.9 stands at 0.80%, this figure is decreased -0.07 in the last six months. The insider ownership for the shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is ticked at 5.14%, the figure is plummeted -13.4% in the last six months.

Some other important financial aspects to be discussed here for Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is the Mean Target Price estimated by the analysts which stands at 78.92. The 52 week high of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is placed at 74.81 and 52 week low is standing at 11.38.

Performance wise the shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) rose up 8.55% for the week, it also rise 13.89% for the monthly performance, while for the quarter it went down 41.9%. The shares increase 113.79% for the half year and flew up for the Year-To-Date performance. The shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) grew 488.14% for the yearly performance.